Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Motavizumab Advisory Committee To Consider Possible Study Bias

This article was originally published in The Pink Sheet Daily

Executive Summary

Concerns FDA raised in its "complete response" letter to MedImmune for its monoclonal antibody Rezield (motavizumab) have not been addressed to the agency's complete satisfaction.

You may also be interested in...



Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune

If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)

Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune

If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)

Would AstraZeneca Be Better Off If Rezield Had Gotten A Harsher FDA Letter?

AstraZeneca subsidiary MedImmune received a "complete response" letter from FDA for its RSV drug motavizumab that did not request additional clinical data, but after an unfavorable advisory committee a year and a half later, the company is looking at the prospect of having to do another trial anyway

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel